当前位置: X-MOL 学术Neurogastroenterol. Motil. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prokinetics‐safety and efficacy: The European Society of Neurogastroenterology and Motility/The American Neurogastroenterology and Motility Society expert review
Neurogastroenterology & Motility ( IF 3.5 ) Pub Date : 2024-03-11 , DOI: 10.1111/nmo.14774
Serhat Bor 1 , İsmail H. Kalkan 2 , Edoardo Savarino 3 , Satish Rao 4 , Jan Tack 5 , Jay Pasricha 6 , David Cangemi 7 , Jolien Schol 8 , Tennekon Karunaratne 9 , Matteo Ghisa 10 , Nitin K. Ahuja 11 , Brian Lacy 12
Affiliation  

BackgroundProkinetics are a class of pharmacological drugs designed to improve gastrointestinal (GI) motility, either regionally or across the whole gut. Each drug has its merits and drawbacks, and based on current evidence as high‐quality studies are limited, we have no clear recommendation on one class or other. However, there remains a large unmet need for both regionally selective and/or globally acting prokinetic drugs that work primarily intraluminally and are safe and without systemic side effects.PurposeHere, we describe the strengths and weaknesses of six classes of prokinetic drugs, including their pharmacokinetic properties, efficacy, safety and tolerability and potential indications.

中文翻译:

Prokinetics-安全性和有效性:欧洲神经胃肠病学和运动学会/美国神经胃肠病学和运动学会专家评审

背景促动力剂是一类药理学药物,旨在改善局部或整个肠道的胃肠道 (GI) 蠕动。每种药物都有其优点和缺点,根据目前的证据,由于高质量研究有限,我们对某一类药物没有明确的建议。然而,对于主要在管腔内起作用且安全且无全身副作用的区域选择性和/或全局作用促动力药物的需求仍然很大。目的在这里,我们描述了六类促动力药物的优点和缺点,包括它们的药代动力学特性、功效、安全性和耐受性以及潜在适应症。
更新日期:2024-03-11
down
wechat
bug